[46] |
Crinò SF, Napoleon B, Facciorusso A, et al. Endoscopic ultrasound-guided radiofrequency ablation versus surgical resection for treatment of pancreatic insulinoma[J]. Clin Gastroenterol Hepatol, 2023, 21(11):2834-2843, e2.
|
[47] |
Napoléon B, Lisotti A, Caillol F, et al. Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study)[J]. Gastrointest Endosc, 2023, 98(3):392-399, e1.
|
[48] |
Barthet M, Giovannini M, Gasmi M, et al. Long-term outcome after EUS-guided radiofrequency ablation: prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms[J]. Endosc Int Open, 2021, 9(8):E1178-1185.
|
[49] |
Barthet M, Giovannini M, Lesavre N, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study[J]. Endoscopy, 2019, 51(9):836-842.
|
[50] |
Marx M, Godat S, Caillol F, et al. Management of non-functional pancreatic neuroendocrine tumors by endoscopic ultrasound-guided radiofrequency ablation: retrospective study in two tertiary centers[J]. Dig Endosc, 2022, 34(6):1207-1213.
|
[51] |
Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size[J]. Ann Surg Oncol, 2013, 20(9):2815-2821.
|
[52] |
Sallinen V, Haglund C, Seppänen H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: do size and symptoms matter?[J]. Surgery, 2015, 158(6):1556-1563.
|
[53] |
Curran T, Pockaj BA, Gray RJ, et al. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection[J]. J Gastrointest Surg, 2015, 19(1):152-160.
|
[54] |
Zhang Z, Wang F, Li Z, et al. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors[J]. BMC Surg, 2022, 22(1):160.
|
[55] |
Parekh JR, Wang SC, Bergsland EK, et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients[J]. Pancreas, 2012, 41(6):840-844.
|
[56] |
Zhang XF, Xue F, Dong DH, et al. New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis[J]. Ann Surg, 2021, 274(1):e28-35.
|
[57] |
Barrett JR, Rendell V, Pokrzywa C, et al. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit[J]. J Surg Oncol, 2020, 121(7):1067-1073.
|
[58] |
Genç CG, Jilesen AP, Partelli S, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors[J]. Ann Surg, 2018, 267(6):1148-1154.
|
[59] |
Wang WQ, Zhang WH, Gao HL, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4):395-405.
|
[60] |
Gao H, Liu L, Wang W, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor[J]. Cancer Lett, 2018, 412: 188-193.
|
[61] |
Han IW, Park J, Park EY, et al. Fate of surgical patients with small nonfunctioning pancreatic neuroendocrine tumors: an international study using multi-institutional registries[J]. Cancers, 2022, 14(4):1038.
|
[1] |
Fan JH, Zhang YQ, Shi SS, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China[J]. Oncotarget, 2017, 8(42):71699-71708.
|
[2] |
吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 协和医学杂志, 2021, 12(4):460-480.
|
[3] |
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10):1335-1342.
|
[4] |
Zhang WH, Xu JF, Hu YH, et al. The surgical and therapeutic activities of non-functional pancreatic neuroendocrine tumors at a high-volume institution[J]. Cancers, 2023, 15(7):1955.
|
[5] |
Mao W, Han X, Lv Y, et al. Propensity score-matched analysis of clinical outcome after enucleation versus regular pancreatectomy in patients with small non-functional pancreatic neuroendocrine tumors[J]. Pancreatology, 2020, 20(2):169-176.
|
[6] |
Tan Q, Wang X, Li Y, et al. Prognostic factors of small non-functional pancreatic neuroendocrine tumors and the risk of lymph node metastasis: a population-level study[J]. Front Endocrinol, 2022, 13:907415.
|
[7] |
Gratian L, Pura J, Dinan M, et al. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States[J]. Ann Surg Oncol, 2014, 21(11):3515-3521.
|
[8] |
Javed AA, Pulvirenti A, Razi S, et al. Grading pancreatic neuroendocrine tumors via endoscopic ultrasound-guided fine needle aspiration: a multi-institutional study[J]. Ann Surg, 2023, 277(6):e1284-1290.
|
[9] |
Partelli S, Mazza M, Andreasi V, et al. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: limitations to apply guidelines into real life[J]. Surgery, 2019, 166(2):157-163.
|
[10] |
Partelli S, Massironi S, Zerbi A, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial[J]. Br J Surg, 2022, 109(12):1186-1190.
|
[11] |
Bolm L, Nebbia M, Wei AC, et al. Long-term outcomes of parenchyma-sparing and oncologic resections in patients with nonfunctional pancreatic neuroendocrine tumors <3 cm in a large multicenter cohort[J]. Ann Surg, 2022, 276(3):522-531.
|
[12] |
Pea A, Yu J, Marchionni L, et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases[J]. Ann Surg, 2020, 271(3):566-573.
|
[13] |
Zhang Z, Liu M, Ji S, et al. Prognostic value and clinical predictors of lymph node metastases in pancreatic neuroendocrine tumors[J]. Pancreas, 2020, 49(3):381-386.
|
[14] |
Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system[J]. Virchows Arch, 2006, 449(4):395-401.
|
[15] |
Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site[J]. Neuroendocrinology, 2016, 103(2):172-185.
|
[16] |
Partelli S, Ramage JK, Massironi S, et al. Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms (ASPEN) ≤2 cm: study protocol for a prospective observational study[J]. Front Med, 2020, 7: 598438.
|
[62] |
Zaidi MY, Lopez-Aguiar AG, Switchenko JM, et al. A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients[J]. Ann Surg, 2019, 270(3):422-433.
|
[17] |
Vega EA, Kutlu OC, Alarcon SV, et al. Clinical prognosticators of metastatic potential in patients with small pancreatic neuroendocrine tumors[J]. J Gastrointest Surg, 2021, 25(10):2593-2599.
|
[18] |
Xu JZ, Wang WQ, Zhang SR, et al. Intrinsic contact between T and N classifications in resected well-moderately differentiated locoregional pancreatic neuroendocrine neoplasms[J]. Ann Surg Oncol, 2018, 25(3):647-654.
|
[19] |
Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: a multi-institutional study of 392 cases[J]. J Surg Oncol, 2019, 120(7):1071-1079.
|
[20] |
Shyr BS, Shyr BU, Chen SC, et al. Impact of tumor grade on pancreatic neuroendocrine tumors[J]. Asian J Surg, 2022, 45(12):2659-2663.
|
[21] |
Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors[J]. J Clin Oncol, 2011, 29(22):3044-3049.
|
[22] |
Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications[J]. Ann Surg, 2012, 256(2):321-325.
|
[23] |
Partelli S, Muffatti F, Andreasi V, et al. A single-center prospective observational study investigating the accuracy of preoperative diagnostic procedures in the assessment of lymph node metastases in nonfunctioning pancreatic neuroendocrine tumors[J]. Ann Surg, 2022, 276(5):921-928.
|
[24] |
Haug A, Auernhammer CJ, Wängler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2009, 36(5):765-770.
|
[25] |
Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors[J]. Virchows Arch, 2002, 440(5):461-475.
|
[26] |
Bahri H, Laurence L, Edeline J, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation[J]. J Nucl Med, 2014, 55(11):1786-1790.
|
[27] |
Binderup T, Knigge U, Johnbeck CB, et al. 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study[J]. J Nucl Med, 2021, 62(6):808-815.
|
[28] |
Nilica B, Waitz D, Stevanovic V, et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle[J]. Eur J Nucl Med Mol Imaging, 2016, 43(9):1585-1592.
|
[29] |
Frumovitz M, Plante M, Lee PS, et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM):a randomised, phase 3, multicentre, non-inferiority trial[J]. Lancet Oncol, 2018, 19(10):1394-1403.
|
[30] |
Lee GW, Park JY, Kim DY, et al. Usefulness of sentinel lymph node mapping using indocyanine green and fluorescent imaging in the diagnosis of lymph node metastasis in endometrial cancer[J].J Obstet Gynaecol, 2021, 41(4):605-611.
|
[31] |
Villegas-Tovar E, Jimenez-Lillo J, Jimenez-Valerio V, et al. Performance of Indocyanine green for sentinel lymph node mapping and lymph node metastasis in colorectal cancer: a diagnostic test accuracy meta-analysis[J]. Surg Endosc, 2020, 34(3):1035-1047.
|
[32] |
Hirono S, Tani M, Kawai M, et al. Identification of the lymphatic drainage pathways from the pancreatic head guided by indocyanine green fluorescence imaging during pancreaticoduodenectomy[J]. Dig Surg, 2012, 29(2):132-139.
|
[33] |
Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature, 2017, 543(7643):65-71.
|
[34] |
Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway[J].J Clin Oncol, 2010, 28(2):245-255.
|
[35] |
Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors[J]. Science, 2011, 331(6021):1199-1203.
|
[36] |
Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations[J]. Science, 2011, 333(6041):425.
|
[37] |
Heaphy CM, Subhawong AP, Hong S M, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes[J]. Am J Pathol, 2011, 179(4):1608-1615.
|
[38] |
VandenBussche CJ, Allison DB, Graham MK, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors[J]. Cancer Cytopathol, 2017, 125(7):544-551.
|
[39] |
Beger HG. Benign tumors of the pancreas-radical surgery versus parenchyma-sparing local resection-the challenge facing surgeons[J]. J Gastrointest Surg, 2018, 22(3):562-566.
|
[40] |
Pea A, Tanno L, Nykänen T, et al. Comparison of oncological and surgical outcomes between formal pancreatic resections and parenchyma-sparing resections for small PanNETs (<2 cm): Pancreas2000 research and educational program (course 9) study protocol[J]. Front Med, 2020, 7:559.
|
[41] |
刘梦奇, 刘文生, 李征, 等. 微创肿瘤剜除术治疗胰腺良性及低度恶性肿瘤60例效果分析[J]. 中华外科杂志, 2022, 60(7):674-679.
|
[42] |
Duconseil P, Marchese U, Ewald J, et al. A pancreatic zone at higher risk of fistula after enucleation[J]. World J Surg Oncol, 2018, 16(1):177.
|
[43] |
Heeger K, Falconi M, Partelli S, et al. Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors[J]. Langenbecks Arch Surg, 2014, 399(3):315-321.
|
[44] |
Brient C, Regenet N, Sulpice L, et al. Risk factors for postoperative pancreatic fistulization subsequent to enucleation[J]. J Gastrointest Surg, 2012, 16(10):1883-1887.
|
[45] |
Goldberg SN. Radiofrequency tumor ablation: principles and techniques[J]. Eur J Ultrasound, 2001, 13(2):129-147.
|